

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 October 2020 (01.10.2020)



(10) International Publication Number
WO 2020/193644 A1

(51) International Patent Classification:

A61P 25/28 (2006.01) A61K 39/00 (2006.01)
C07K 16/18 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2020/058395

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:

25 March 2020 (25.03.2020)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/823,785 26 March 2019 (26.03.2019) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: VAN BROECK, Bianca; Turnhoutseweg 30,
2340 Beerse (BE). MERCKEN, Marc; Turnhoutseweg
30, 2340 Beerse (BE). EDWARDS, Wilson; 1940 Glas-
gow Avenue, Cardiff by the Sea, California 92007 (US).
SINGH, Sanjaya; 1400 McKean Road, Spring House,
Pennsylvania 19477 (US). LUO, Jinquan; 1400 McK-
ean Road, Spring House, Pennsylvania 19477 (US). LA
PORTE, Sherry; 1400 McKean Road, Spring House,
Pennsylvania 19477 (US). GANESAN, Rajkumar; 1400
McKean Road, Spring House, Pennsylvania 19477 (US).
HUANG, Chichi; 22 Dobs Lane, Malvern, Pennsylvania
19355 (US).

(74) Agent: DUFFIELD, Stephen et al.; Carpmaels & Ransford
LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIBODIES TO PYROGLUTAMATE AMYLOID- β AND USES THEREOF

(57) Abstract: The invention provides antibodies or antigen binding fragments thereof that bind to 3pE A β and methods of making and using the antibodies or antigen binding fragments thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β -amyloid-related diseases.

WO 2020/193644 A1